Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron Corporation (Nasdaq: GERN) announced plans for a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival as the primary endpoint, expected to start in Q1 2021. The trial will evaluate imetelstat in about 320 patients who are refractory to JAK inhibitors. Additionally, Geron aims to complete patient enrollment in the ongoing IMerge Phase 3 trial for lower risk myelodysplastic syndromes (MDS) by Q1 2021. The company revised its 2020 operating expenses guidance to $70-$75 million due to COVID-19 impacts and trial preparations.